EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tofacitinib for the treatment of chronic pouchitis: A pilot study

Djuna C de Jong iD, Rogier Goetgebuer, Bart L M Müskens, E Andra Neefjes-Borst, Krisztina B Gecse, Mark Löwenberg, Wouter de Jonge, Willem Bemelman, Cyriel Ponsioen, Geert R D'Haens, Marjolijn Duijvestein

United European Gastroenterology Journal · 2025-03 · 13 (2) · 201-209

DOI: 10.1002/ueg2.12683 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 02.02.2025. Verfasst von Djuna C de Jong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Piperidines, Pyrimidines, Pouchitis, Colitis, Ulcerative. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Up to 15% of ulcerative colitis (UC) patients with an ileo‐anal pouch will develop chronic or antibiotic refractory pouchitis. We aimed to evaluate the efficacy and safety of tofacitinib in these refractory patients.

Methods

In this prospective single center study, adult UC patients with chronic or antibiotic refractory pouchitis (pouchitis disease activity index [PDAI] ≥ 7) were treated with tofacitinib 10 mg twice daily for 8 weeks. Clinical, biochemical, endoscopic and histologic disease activity was assessed at baseline and at week 8. The primary endpoint was the proportion of patients achieving clinical remission (PDAI < 7 and a reduction of ≥3 points from baseline) or clinical response (decrease ≥2 points from baseline).

Results

Thirteen patients were included and treated with tofacitinib. After 8 weeks, 31% achieved PDAI‐defined remission (4/13) and 54% achieved response (7/13). Both the total PDAI score (11 [interquartile range 9–12.75] vs. 8 [4.5–9.75], p = 0.033) and the clinical PDAI subscore (4 [3–4] vs. 2 [0.25–3.75], p = 0.014) decreased significantly from baseline compared to week 8 or early withdrawal, respectively. We did not observe a change in endoscopic or histological PDAI subscores.

Conclusion

In this pilot study, clinical remission in patients with chronic pouchitis was achieved in 31% of patients after 8 weeks of treatment with tofacitinib. Total and clinical PDAI dropped significantly compared with baseline, but we did not observe a significant change in endoscopic or histologic disease activity. Presumably, a treatment duration of 8 weeks is insufficient to induce mucosal healing in these refractory patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesPyrimidinesPouchitisColitis, UlcerativeProtein Kinase InhibitorsPyrrolesHumansPilot ProjectsFemaleMaleAdultMiddle AgedProspective StudiesTreatment OutcomeChronic DiseaseRemission InductionSeverity of Illness IndexAnti-Bacterial Agents

Stichwörter der Autor:innen

CARPJAKiJAK‐inhibitorsPDAIantibiotic refractory chronic pouchitisanti‐Jakclinical remissionclinical responsesmall moleculesulcerative colitis

Substanzen

tofacitinibPiperidinesPyrimidinesProtein Kinase InhibitorsPyrrolesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam UMC, Amsterdam, The Netherlands.
  • Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Surgery, Amsterdam UMC, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, Radboudumc, Nijmegen, The Netherlands.

ORCID-Profile: Djuna C de Jong

Förderung

  • Pfizer

Zitieren

APA

de Jong, D. C., Goetgebuer, R., Müskens, B. L. M., Neefjes-Borst, E. A., Gecse, K. B., Löwenberg, M., de Jonge, W., Bemelman, W., Ponsioen, C., D'Haens, G. R., & Duijvestein, M. (2025). Tofacitinib for the treatment of chronic pouchitis: A pilot study. United European Gastroenterology Journal, 13(2), 201-209. https://doi.org/10.1002/ueg2.12683

Vancouver

de Jong DC, Goetgebuer R, Müskens BLM, Neefjes-Borst EA, Gecse KB, Löwenberg M, et al. Tofacitinib for the treatment of chronic pouchitis: A pilot study. United European Gastroenterology Journal. 2025;13(2):201-209. doi:10.1002/ueg2.12683

BibTeX
@article{deJong2025,
  author = {de Jong, Djuna C and Goetgebuer, Rogier and Müskens, Bart L M and Neefjes-Borst, E Andra and Gecse, Krisztina B and Löwenberg, Mark and de Jonge, Wouter and Bemelman, Willem and Ponsioen, Cyriel and D'Haens, Geert R and Duijvestein, Marjolijn},
  title = {Tofacitinib for the treatment of chronic pouchitis: A pilot study},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {2},
  pages = {201--209},
  doi = {10.1002/ueg2.12683}
}
Kostenlos starten →